Medicus Pharma (MDCX) Fundamental Analysis: Revenue, Earnings & Valuation

3.28 / 10

Netural

Fundamental analysis rates neutral, scoring 3.3/10. Profit‑MV and Cash‑MV are positive, while Inventory turnover is strong. Asset‑MV, Revenue‑MV and Income‑tax/Profit ratios lag, indicating limited profitability and asset efficiency concerns.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight16.33%

1M Return5.44%

Inventory turnover ratio

Value47.57

Score3/3

Weight19.82%

1M Return6.65%

Gross profit margin (%)

Value36.91

Score1/3

Weight0.77%

1M Return0.36%

Profit-MV

Value0.41

Score2/3

Weight18.64%

1M Return6.36%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight0.46%

1M Return0.21%

Current assets turnover ratio

Value1.78

Score2/3

Weight4.28%

1M Return1.91%

Fixed assets turnover ratio

Value7899.90

Score3/3

Weight3.95%

1M Return1.76%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight9.85%

1M Return4.08%

Asset-MV

Value-0.48

Score0/3

Weight7.65%

1M Return2.73%

Cash-MV

Value-0.09

Score2/3

Weight18.26%

1M Return6.19%

Is MDCX fundamentally strong?

MDCX scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -2765.39% ROE, 0.00% net margin, -0.74 P/E ratio, 338.21 P/B ratio, and -136.21% earnings growth, these metrics solidify its Netural investment rating.